Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche's Tecentriq Becomes Second In PD-1/L1 Family To Gain First-Line Lung Cancer Approval

Executive Summary

The PD-L1 inhibitor's label excludes NSCLC patients with EGFR or ALK mutations, which could have been an advantage, but the indication largely reflects the registrational IMpower150 clinical trial's population.

Advertisement

Related Content

Keeping Track: Some Calm Before The Storm
Mystic Miss Not Make Or Break For Imfinzi
Keytruda Is King, But Merck Faces Questions About Business Development
Amid PD-1 Uncertainty, Bristol Under Pressure For M&A Activity
Tecentriq's Small-Cell Lung Cancer Success Takes Edge Off Roche's IO Position
AstraZeneca's PACIFIC Update Bolsters Imfinzi's Lead In Stage III Lung Cancer
Roche's IMpower150 Gets AACR Applause But Merck's KEYNOTE-189 Big Winner
Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124304

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel